News & Updates
Filter by Specialty:
SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.
SLE rash treatment better with GC plus hydroxychloroquine combo vs GC monotherapy
16 Sep 2023
Which factors predict sustained RA remission with MTX or ETN monotherapy?
Following the switch from combination therapy to monotherapy, rheumatoid arthritis (RA) patients with overall lower disease activity (LDA) have higher odds of achieving and remaining in Simplified Disease Activity Index (SDAI) remission/LDA, suggests a study.
Which factors predict sustained RA remission with MTX or ETN monotherapy?
12 Sep 2023
Glucocorticoid discontinuation may prevent infection in older RA patients
For older patients with rheumatoid arthritis (RA) who are receiving glucocorticoids (GCs), stopping its use lowers the incidence of infection, according to a study.
Glucocorticoid discontinuation may prevent infection in older RA patients
05 Aug 2023
Saphnelo now available in Malaysia as an add-on treatment for adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)
AstraZeneca’s Saphnelo (anifrolumab) has now become available as add-on treatment for adult patients in Malaysia with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE) following insufficient response to standard therapy, after obtaining regulatory approval earlier this year.
